Parathyroid Carcinoma Clinical Trial
Official title:
Parathyroid Cancer Versus Atypical Parathyroid Neoplasm; Investigating Their Clinical Characteristics and Biological Behavior
Verified date | February 2018 |
Source | M.D. Anderson Cancer Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Objectives:
1. Identify the clinical characteristics of parathyroid (PTH) cancer and PTH atypical
neoplasms
2. Investigate if PTH carcinoma and atypical neoplasm present a biological behaviour and
have a different impact on the health of the patients
Status | Completed |
Enrollment | 100 |
Est. completion date | October 16, 2017 |
Est. primary completion date | October 16, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - All patients from MDACC diagnosed with PHPT that have a histopathological diagnosis of PTH carcinoma or atypical parathyroid neoplasm between the years 1/1/2002 and 12/31/2013 Exclusion Criteria: - Pediatric patients - Cases with incomplete records - Patients where the follow-up will be less than six months |
Country | Name | City | State |
---|---|---|---|
United States | University of Texas MD Anderson Cancer Center | Houston | Texas |
Lead Sponsor | Collaborator |
---|---|
M.D. Anderson Cancer Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Information Collected on Clinical Characteristics of Parathyroid (PTH) Cancer and PTH Atypical Neoplasms by Conducting a Retrospective Chart Review | 5 years | ||
Primary | Information Collected on PTH Carcinoma's Biological Behaviour and Impact on the Health of the Patients by Conducting a Retrospective Chart Review | 5 years | ||
Primary | Information Collected on Atypical Neoplasm's Biological Behaviour and Impact on the Health of the Patients \by Conducting a Retrospective Chart Review | 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00580320 -
Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma
|
Phase 1 | |
Completed |
NCT01460030 -
An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism
|
Phase 3 | |
Recruiting |
NCT05789680 -
European Multicentric Study on Parathyroid Carcinoma
|
||
Completed |
NCT03280264 -
Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism
|
Phase 3 |